Do analysts recommend LIAN or SPRC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, LIAN or SPRC?

SciSparc has higher revenue and earnings than LianBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A SciSparc $860K 3.17 -$12.18M N/A N/A

Is LIAN or SPRC more profitable?

SciSparc's return on equity of 0.00% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% SciSparc N/A N/A N/A

Do analysts rate SPRC or GDTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, SPRC or GDTC?

CytoMed Therapeutics has lower revenue, but higher earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.17 -$12.18M N/A N/A CytoMed Therapeutics $324.39K 35.60 -$3.10M N/A N/A

Is SPRC or GDTC more profitable?

Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A CytoMed Therapeutics N/A N/A N/A

Do analysts recommend SPRC or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, SPRC or BFRI?

Biofrontera has higher revenue and earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $860K 3.17 -$12.18M N/A N/A Biofrontera $41.71M 0.31 -$10.54M -$0.97 N/A

Is SPRC or BFRI more profitable?

SciSparc has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. SciSparc's return on equity of 0.00% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A Biofrontera -25.66% -515.34% -53.91%

Do analysts recommend PHIO or SPRC?

Phio Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PHIO or SPRC?

Phio Pharmaceuticals has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A SciSparc $860K 3.17 -$12.18M N/A N/A

Is PHIO or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% SciSparc N/A N/A N/A

Which has better earnings and valuation, JSPR or SPRC?

SciSparc has higher revenue and earnings than Jasper Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A SciSparc $860K 3.17 -$12.18M N/A N/A

Is JSPR or SPRC more profitable?

SciSparc's return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% SciSparc N/A N/A N/A

SciSparc (SPRC) Competitors

$4.78 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.85 +0.07 (+1.46%)

As of 07/2/2026 04:38 PM Eastern

Compare

SPRC vs. LIAN, GDTC, BFRI, PHIO, and JSPR

Should you buy SciSparc stock or one of its competitors? MarketBeat compares SciSparc with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SciSparc include LianBio (LIAN), CytoMed Therapeutics (GDTC), Biofrontera (BFRI), Phio Pharmaceuticals (PHIO), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry.

How does SciSparc compare to LianBio?

LianBio (NASDAQ:LIAN) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

74.8% of LianBio shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SciSparc has higher revenue and earnings than LianBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
SciSparc	$860K	3.17	-$12.18M	N/A	N/A

In the previous week, LianBio's average media sentiment score of 0.00 equaled SciSparc'saverage media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
SciSparc	Neutral

LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc's return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
SciSparc	N/A	N/A	N/A

Summary

SciSparc beats LianBio on 6 of the 8 factors compared between the two stocks.

How does SciSparc compare to CytoMed Therapeutics?

SciSparc (NASDAQ:SPRC) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

25.1% of SciSparc shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

In the previous week, SciSparc's average media sentiment score of 0.00 equaled CytoMed Therapeutics'average media sentiment score.

Company	Overall Sentiment
SciSparc	Neutral
CytoMed Therapeutics	Neutral

CytoMed Therapeutics has lower revenue, but higher earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.17	-$12.18M	N/A	N/A
CytoMed Therapeutics	$324.39K	35.60	-$3.10M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
CytoMed Therapeutics	N/A	N/A	N/A

Summary

SciSparc beats CytoMed Therapeutics on 4 of the 6 factors compared between the two stocks.

How does SciSparc compare to Biofrontera?

SciSparc (NASDAQ:SPRC) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

SciSparc has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. SciSparc's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
Biofrontera	-25.66%	-515.34%	-53.91%

SciSparc has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

25.1% of SciSparc shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 1.5% of SciSparc shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860K	3.17	-$12.18M	N/A	N/A
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A

In the previous week, SciSparc's average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company	Overall Sentiment
SciSparc	Neutral
Biofrontera	Neutral

Summary

SciSparc beats Biofrontera on 6 of the 11 factors compared between the two stocks.

How does SciSparc compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than SciSparc. MarketBeat recorded 1 mentions for Phio Pharmaceuticals and 0 mentions for SciSparc. Phio Pharmaceuticals' average media sentiment score of 1.00 beat SciSparc's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
SciSparc	Neutral

Phio Pharmaceuticals has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
SciSparc	$860K	3.17	-$12.18M	N/A	N/A

Phio Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phio Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SciSparc's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
SciSparc	N/A	N/A	N/A

Summary

Phio Pharmaceuticals beats SciSparc on 7 of the 12 factors compared between the two stocks.

How does SciSparc compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 2.3% of Jasper Therapeutics shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SciSparc's return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
SciSparc	N/A	N/A	N/A

Jasper Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the broader market. Comparatively, SciSparc has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market.

Jasper Therapeutics presently has a consensus price target of $13.14, indicating a potential upside of 2,968.61%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jasper Therapeutics is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jasper Therapeutics had 2 more articles in the media than SciSparc. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for SciSparc. Jasper Therapeutics' average media sentiment score of 0.00 equaled SciSparc'saverage media sentiment score.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
SciSparc	Neutral

SciSparc has higher revenue and earnings than Jasper Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
SciSparc	$860K	3.17	-$12.18M	N/A	N/A

Summary

Jasper Therapeutics beats SciSparc on 7 of the 11 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRC vs. The Competition

Export

Metric	SciSparc	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.70M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	N/A	20.06	28.02	24.70
Price / Sales	3.17	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.37	4.32	10.96	6.46
Net Income	-$12.18M	$64.45M	$3.57B	$337.01M
7 Day Performance	-16.14%	2.97%	2.12%	1.69%
1 Month Performance	-58.22%	6.83%	5.25%	3.81%
1 Year Performance	-92.22%	29.07%	33.29%	23.90%

SciSparc Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRC SciSparc	0.8597 of 5 stars	$4.78 flat	N/A	-92.2%	$2.70M	$860K	N/A	4	Gap Down
LIAN LianBio	N/A	$0.12 flat	N/A	-73.5%	$12.43M	N/A	N/A	110
GDTC CytoMed Therapeutics	1.058 of 5 stars	$1.03 -0.5%	N/A	-53.5%	$12.19M	$250K	N/A	N/A	Gap Down
BFRI Biofrontera	1.0246 of 5 stars	$1.01 +6.8%	N/A	+43.1%	$12.11M	$41.71M	N/A	70
PHIO Phio Pharmaceuticals	4.1636 of 5 stars	$1.00 -2.4%	$14.00 +1,300.0%	-58.9%	$11.91M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SciSparc (SPRC) Competitors

SPRC vs. LIAN, GDTC, BFRI, PHIO, and JSPR

How does SciSparc compare to LianBio?

Summary

How does SciSparc compare to CytoMed Therapeutics?

Summary

How does SciSparc compare to Biofrontera?

Summary

How does SciSparc compare to Phio Pharmaceuticals?

Summary

How does SciSparc compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SciSparc (SPRC) Competitors

SPRC vs. LIAN, GDTC, BFRI, PHIO, and JSPR

How does SciSparc compare to LianBio?

Do insiders and institutionals believe in LIAN or SPRC?

Which has higher valuation & earnings, LIAN or SPRC?

Does the media prefer LIAN or SPRC?

Which has more risk and volatility, LIAN or SPRC?

Do analysts recommend LIAN or SPRC?

Is LIAN or SPRC more profitable?

Summary

How does SciSparc compare to CytoMed Therapeutics?

Do institutionals and insiders believe in SPRC or GDTC?

Do analysts rate SPRC or GDTC?

Which has more volatility and risk, SPRC or GDTC?

Does the media favor SPRC or GDTC?

Which has higher earnings and valuation, SPRC or GDTC?

Is SPRC or GDTC more profitable?

Summary

How does SciSparc compare to Biofrontera?

Is SPRC or BFRI more profitable?

Which has more volatility and risk, SPRC or BFRI?

Do institutionals & insiders hold more shares of SPRC or BFRI?

Do analysts recommend SPRC or BFRI?

Which has stronger earnings & valuation, SPRC or BFRI?

Does the media refer more to SPRC or BFRI?

Summary

How does SciSparc compare to Phio Pharmaceuticals?

Does the media refer more to PHIO or SPRC?

Which has stronger earnings & valuation, PHIO or SPRC?

Which has more volatility and risk, PHIO or SPRC?

Do insiders and institutionals believe in PHIO or SPRC?

Do analysts recommend PHIO or SPRC?

Is PHIO or SPRC more profitable?

Summary

How does SciSparc compare to Jasper Therapeutics?

Do insiders & institutionals believe in JSPR or SPRC?

Is JSPR or SPRC more profitable?

Which has more risk & volatility, JSPR or SPRC?

Do analysts recommend JSPR or SPRC?

Does the media refer more to JSPR or SPRC?

Which has better earnings and valuation, JSPR or SPRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC vs. The Competition

SciSparc Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools